Other Events ·
Jaguar Health, Inc. announced on June 22, 2026, that its Board of Directors has initiated a process to explore and…
JAGXJaguar Health, Inc.
Jaguar Health, Inc. announced on June 22, 2026, that its Board of Directors has initiated a process to explore and review a range of strategic alternatives to maximize shareholder value. The company expects this process to align with the anticipated completion of clinical work for its crofelemer prescription drug candidate for rare intestinal failure diseases. Jaguar Health, Inc. is a healthcare company focused on the development and of the commercialization of prescription drugs for rare intestinal failure diseases.